|
2005 Research
Page Two
24 vs 48 weeks
Pegasys/RBV in HCV Genotype 2/3 Coinfection:
does this study answer the question
Sep 01 2005
Treatment of
Genotype 4 HCV
Aug 10 2005
European Union's CHMP Adopts Positive Opinion for Shorter Course of
PEGINTRON(R) and REBETOL(R) Combination Therapy for Certain Hepatitis C
Patients with Genotype 1 and Low Viral Load
Aug 4 2005
Peginterferon-α-2a
(40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3
Chronic Hepatitis C
Aug 3 2005
Short Term Therapy for Genotype 2a
June 04 2005
Enrollment
Completed for Phase IIb Trial of Valopicitabine plus Pegasys Combination
Therapy for HCV Genotype 1 Patients Non-responsive to
Peginterferon/Ribavirin
June 01 2005
Etanercept
Treatment to Slow Fibrosis Progression Shows No Histological or Biochemical
Improvement in Chronic HCV Genotype 1 Nonresponders to
Peginterferon/Ribavirin
June 01 2005
Predictors of
Treatment Failure in Patients with Hepatitis C Genotypes 2 or 3
June 01 2005
Efficacy of 24
Weeks of Treatment with Peginterferon Alfa-2b (PegIntron) Plus Ribavirin in
Patients with HCV Genotype 1 and Low Viral Load
May 30 2005
Page One
Peginterferon
Alfa-2a/ribavirin Treatment in Patients with Chronic HCV Genotype 1:
Efficacy Is Improved in Patients with Early Stages of Fibrosis
May 18 2005
Peginterferon
Alfa-2b (PegIntron) Therapy for 8 Weeks in Acute Hepatitis C Genotypes 1 and
4: A Pilot Study
May 18 2005
Efficacy
of Daily Consensus Interferon (Infergen) and Ribavirin Compared to
Peg-Interferon Alfa2b (PegIntron) and Ribavirin in Treatment-Naive Patients
with HCV Genotype 2 or 3
May 15 2005
No Correlation
Found Between Steatosis and Liver Fibrosis in HCV Genotype 1 Infection
May 05 2005
HCV genotype 5
has a similar response to peginterferon plus ribavirin as genotype 1
April 19 2005
In Genotype 1
Patients with Low Viral Load Who Become HCV RNA Negative at Week 4,
Treatment with Peginterferon Alfa-2b (PegIntron) for 24 Weeks Has Similar
High Efficacy with Superior Safety Compared to 48-week Therapy
DOES THE CLINICAL OUTCOME OF HEPATITIS C INFECTION VARY WITH THE INFECTING
HEPATITIS C VIRUS TYPE?
April 19 2005
Nine of 10
Chronic Hepatitis C Patients Achieve a Cure 24 Weeks Post-treatment with
High Dose Ribavirin Plus Standard Dose Peginterferon Alfa-2a (Pegasys)
Response to
Treatment in Patients with HCV Genotype 5
Budget Impact
Analysis of 2 Different Methods of Evaluating Early Viral Response to Peginterferon Alfa-2b (Peg-Intron) Plus Ribavirin Therapy in Genotype 1
Patients
Comparison of 2 Doses of
Peginterferon Alfa-2b Plus Weight-based Ribavirin for Treatment-naïve
Patients with Genotype 1 HCV
Research Archives
(Back
to : Archives With All 2004 - 2001 Research
)
|
